Analysis of treatment for small cell cancer of the bladder and report of three cases

Edward Karpman, Zelanna Goldberg, Amir Saffarian, Regina F Gandour-Edwards, Lars M. Ellison, Ralph W deVere White

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objectives To present our experience with 3 patients with small cell cancer (SCC) of the bladder who were treated with different modalities and review the literature for patients undergoing primary chemoradiotherapy. SCC of the bladder is a rare tumor, with patients commonly presenting with metastatic disease. Surgery, radiotherapy, and chemotherapy, either alone or as part of combined therapy, have been used. Because of the rarity of this disease, no prospective studies evaluating the most effective treatment have been done. Methods The medical records of 3 patients diagnosed with SCC of the bladder at our institution were reviewed. Additionally, we reviewed published reports to identify all cases of SCC of the bladder treated with primary chemoradiotherapy. Results Three patients with SCC of the bladder were identified at our institution. A total of 23 patients with SCC of the bladder who were treated with primary chemoradiotherapy were identified: 22 in published reports and 1 at our institution. Patients presented with muscle-invasive disease (17%), extravesical disease only (26%), and metastatic disease (52%). Multiagent chemotherapy was administered to most patients. The reported median radiation dose was 6000 cGy. A total of 16 patients (70%) were alive at a median follow-up of 34 months. The median survival of patients had not yet been reached in this study at the last follow-up. We did not find any reports of SCC recurrence in the bladder, and the bladder was preserved in most patients (87%). Conclusions SCC of the bladder should be viewed as a systemic disease, because most patients present with metastatic disease. Primary chemoradiotherapy appears to be an effective treatment modality. Prospective studies are needed to evaluate the optimal treatment further.

Original languageEnglish (US)
Pages (from-to)494-498
Number of pages5
JournalUrology
Volume64
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

Urinary Bladder Neoplasms
Chemoradiotherapy
Therapeutics
Urinary Bladder
Prospective Studies
Drug Therapy
Medical Records
Neoplasms
Radiotherapy
Radiation
Recurrence
Muscles
Survival

ASJC Scopus subject areas

  • Urology

Cite this

Analysis of treatment for small cell cancer of the bladder and report of three cases. / Karpman, Edward; Goldberg, Zelanna; Saffarian, Amir; Gandour-Edwards, Regina F; Ellison, Lars M.; deVere White, Ralph W.

In: Urology, Vol. 64, No. 3, 09.2004, p. 494-498.

Research output: Contribution to journalArticle

Karpman, Edward ; Goldberg, Zelanna ; Saffarian, Amir ; Gandour-Edwards, Regina F ; Ellison, Lars M. ; deVere White, Ralph W. / Analysis of treatment for small cell cancer of the bladder and report of three cases. In: Urology. 2004 ; Vol. 64, No. 3. pp. 494-498.
@article{e5fd39f297764c199f00144f25f91e75,
title = "Analysis of treatment for small cell cancer of the bladder and report of three cases",
abstract = "Objectives To present our experience with 3 patients with small cell cancer (SCC) of the bladder who were treated with different modalities and review the literature for patients undergoing primary chemoradiotherapy. SCC of the bladder is a rare tumor, with patients commonly presenting with metastatic disease. Surgery, radiotherapy, and chemotherapy, either alone or as part of combined therapy, have been used. Because of the rarity of this disease, no prospective studies evaluating the most effective treatment have been done. Methods The medical records of 3 patients diagnosed with SCC of the bladder at our institution were reviewed. Additionally, we reviewed published reports to identify all cases of SCC of the bladder treated with primary chemoradiotherapy. Results Three patients with SCC of the bladder were identified at our institution. A total of 23 patients with SCC of the bladder who were treated with primary chemoradiotherapy were identified: 22 in published reports and 1 at our institution. Patients presented with muscle-invasive disease (17{\%}), extravesical disease only (26{\%}), and metastatic disease (52{\%}). Multiagent chemotherapy was administered to most patients. The reported median radiation dose was 6000 cGy. A total of 16 patients (70{\%}) were alive at a median follow-up of 34 months. The median survival of patients had not yet been reached in this study at the last follow-up. We did not find any reports of SCC recurrence in the bladder, and the bladder was preserved in most patients (87{\%}). Conclusions SCC of the bladder should be viewed as a systemic disease, because most patients present with metastatic disease. Primary chemoradiotherapy appears to be an effective treatment modality. Prospective studies are needed to evaluate the optimal treatment further.",
author = "Edward Karpman and Zelanna Goldberg and Amir Saffarian and Gandour-Edwards, {Regina F} and Ellison, {Lars M.} and {deVere White}, {Ralph W}",
year = "2004",
month = "9",
doi = "10.1016/j.urology.2004.04.038",
language = "English (US)",
volume = "64",
pages = "494--498",
journal = "Urology",
issn = "1527-9995",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Analysis of treatment for small cell cancer of the bladder and report of three cases

AU - Karpman, Edward

AU - Goldberg, Zelanna

AU - Saffarian, Amir

AU - Gandour-Edwards, Regina F

AU - Ellison, Lars M.

AU - deVere White, Ralph W

PY - 2004/9

Y1 - 2004/9

N2 - Objectives To present our experience with 3 patients with small cell cancer (SCC) of the bladder who were treated with different modalities and review the literature for patients undergoing primary chemoradiotherapy. SCC of the bladder is a rare tumor, with patients commonly presenting with metastatic disease. Surgery, radiotherapy, and chemotherapy, either alone or as part of combined therapy, have been used. Because of the rarity of this disease, no prospective studies evaluating the most effective treatment have been done. Methods The medical records of 3 patients diagnosed with SCC of the bladder at our institution were reviewed. Additionally, we reviewed published reports to identify all cases of SCC of the bladder treated with primary chemoradiotherapy. Results Three patients with SCC of the bladder were identified at our institution. A total of 23 patients with SCC of the bladder who were treated with primary chemoradiotherapy were identified: 22 in published reports and 1 at our institution. Patients presented with muscle-invasive disease (17%), extravesical disease only (26%), and metastatic disease (52%). Multiagent chemotherapy was administered to most patients. The reported median radiation dose was 6000 cGy. A total of 16 patients (70%) were alive at a median follow-up of 34 months. The median survival of patients had not yet been reached in this study at the last follow-up. We did not find any reports of SCC recurrence in the bladder, and the bladder was preserved in most patients (87%). Conclusions SCC of the bladder should be viewed as a systemic disease, because most patients present with metastatic disease. Primary chemoradiotherapy appears to be an effective treatment modality. Prospective studies are needed to evaluate the optimal treatment further.

AB - Objectives To present our experience with 3 patients with small cell cancer (SCC) of the bladder who were treated with different modalities and review the literature for patients undergoing primary chemoradiotherapy. SCC of the bladder is a rare tumor, with patients commonly presenting with metastatic disease. Surgery, radiotherapy, and chemotherapy, either alone or as part of combined therapy, have been used. Because of the rarity of this disease, no prospective studies evaluating the most effective treatment have been done. Methods The medical records of 3 patients diagnosed with SCC of the bladder at our institution were reviewed. Additionally, we reviewed published reports to identify all cases of SCC of the bladder treated with primary chemoradiotherapy. Results Three patients with SCC of the bladder were identified at our institution. A total of 23 patients with SCC of the bladder who were treated with primary chemoradiotherapy were identified: 22 in published reports and 1 at our institution. Patients presented with muscle-invasive disease (17%), extravesical disease only (26%), and metastatic disease (52%). Multiagent chemotherapy was administered to most patients. The reported median radiation dose was 6000 cGy. A total of 16 patients (70%) were alive at a median follow-up of 34 months. The median survival of patients had not yet been reached in this study at the last follow-up. We did not find any reports of SCC recurrence in the bladder, and the bladder was preserved in most patients (87%). Conclusions SCC of the bladder should be viewed as a systemic disease, because most patients present with metastatic disease. Primary chemoradiotherapy appears to be an effective treatment modality. Prospective studies are needed to evaluate the optimal treatment further.

UR - http://www.scopus.com/inward/record.url?scp=4444338816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444338816&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2004.04.038

DO - 10.1016/j.urology.2004.04.038

M3 - Article

C2 - 15351578

AN - SCOPUS:4444338816

VL - 64

SP - 494

EP - 498

JO - Urology

JF - Urology

SN - 1527-9995

IS - 3

ER -